MedTrace Logo

Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)

NCT00312858 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 653

Last updated 2017-04-13

Study results available
· View outcomes & findings →

Summary

Hepatitis A vaccine will be given either alone or together with measles, mumps, rubella, and varicella vaccine and pneumococcal 7-valent conjugate vaccine at the first dose and together with measles, mumps, rubella, and varicella \[Oka/Merck\] virus vaccine at the second dose. Immunogenicity and safety data will be collected after each dose of vaccine.

Conditions

  • Hepatitis A Virus

Interventions

BIOLOGICAL

Comparator: VAQTA™ (Hepatitis A vaccine)

VAQTA™ 0.5 mL injection

BIOLOGICAL

Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine)

ProQuad™ 0.5 mL injection

BIOLOGICAL

Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine)

Prevnar™ 0.5 mL injection

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Months
Max Age
15 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2008-03-31
Completion
2008-03-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00312858 on ClinicalTrials.gov